VNRX News and Press, VolitionRX Limited From 08/10/22

VolitionRX press release ( NYSE: VNRX ): Q2 Cash and cash equivalents as of June 30, 2022, totaled approximately $16.7 million compared with $20.6 million as of December 31, 2021 Continued to manage expenditures carefully with net cash used in operating activities averagin...

VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update PR Newswire Conference call to discuss financial and operational results scheduled for Thursday, August 11 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada ...

VolitionRX ( NYSE: VNRX ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.14 (-40.0% Y/Y) and the consensus Revenue Estimate is $0.11M (+450.0% Y/Y). Over the last 3 months, EPS estimates have...

Volition Announces U.S. Clinical Study for NETs PR Newswire HENDERSON, Nev. , Aug. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a sponsored research agreement with The ...

VolitionRx ( NYSE: VNRX ) said it appointed Diagnostic Oncology CRO (DXOCRO) to undertake development and clinical validation studies of its Nu.Q cancer tests portfolio in the U.S. DXOCRO will conduct large-scale finding studies at multiple sites in the U.S. using...

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy PR Newswire HENDERSON, Nev. , Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC ("DX...

VolitionRx ( NYSE: VNRX ) received a further $1.5M non-dilutive funding from Namur Invest Capital Risk in Belgium. The funding is unsecured, bears interest at a rate of 6% per year and is repayable over four years with a maturity date of July 31, 2026. Namur ...

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding PR Newswire HENDERSON, Nev. , Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $...

Henderson, Nevada--(Newsfile Corp. - August 3, 2022) - VolitionRx Limited (NYSE American: VNRX) today announced that company executives Cameron Reynolds, CEO, and Scott Powell, Head of Investor Relations, will be attending the Q3 Virtual Investor Summit. During the presentation, VolitionRx L...

VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev. , Aug. 2, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, ...